Senior vice president, market solutions at Turquoise Health
Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial Hurdles
June 29th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.
Biosimilar Misconceptions, PBM Transparency, and Value-Based Care: Insights From Canavan & O'Dell
June 15th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain the misconception that cheaper biosimilars automatically lead to lower costs due to pharmacy benefit manager (PBM) spread pricing, while also highlighting major PBM trends toward increased transparency, value-based care, and efforts to reduce prescription costs.